English
Home > Products > 113507-06-5

China 113507-06-5 Factory

Assume full responsibility to satisfy all needs of our clients; achieve continual advancements by endorsing the expansion of our purchasers; turn into the final permanent cooperative partner of clientele and maximize the interests of clients for 113507-06-5,CAS NO 113507-06-5,Moxidectin API,Moxidectin, Customers' profit and pleasure are constantly our biggest goal. You should contact us. Give us a probability, offer you a surprise.
113507-06-5, We believe in establishing healthy customer relationships and positive interaction for business. Close cooperation with our customers has helped us to create strong supply chains and reap benefits. Our products and solutions have gained us widespread acceptance and the satisfaction of our worldwide valued clients.

Related Products

Hot Products

  • 1-Bromo-2,3-difluorobenzene

    1-Bromo-2,3-difluorobenzene

    Product Name:1-Bromo-2,3-difluorobenzene
    Molecular Formula:C6H3BrF2
    Molecular Weight:192.99
    CAS Registry Number:38573-88-5
  • Mobocertinib succinate

    Mobocertinib succinate

    Product Name:Mobocertinib succinate
    Molecular Formula:C36H45N7O8
    Molecular Weight;703.8
    CAS Registry Number;2389149-74-8
  • Felodipine

    Felodipine

    Product Name:Felodipine
    Molecular Formula:C18H19Cl2NO4
    Molecular Weight;384.25
    CAS Registry Number;72509-76-3/86189-69-7
  • 1-Cyclopropyl Piperazine

    1-Cyclopropyl Piperazine

    Product Name:1-Cyclopropyl Piperazine
    Molecular Formula:C8H14N2O
    Molecular Weight:154.21
    CAS Registry Number:59878-57-8
  • Potassium hydroxide

    Potassium hydroxide

    Product Name:Potassium hydroxide
    Molecular Formula:KOH
    Molecular Weight:56.11
    CAS Registry Number:1310-58-3
  • 2-Imidazolidone

    2-Imidazolidone

    Product Name:2-Imidazolidone
    Molecular Formula:C3H6N2O
    Molecular Weight:86.09
    CAS Registry Number:120-93-4
  • Related Blog
  • Reviews

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

  • What Is Ursodeoxycholic Acid Used For?

    Ursodeoxycholic acid is a cholelithiant commonly used in the gastroenterology department, and also a cholelithiasis dissolving agent, so it can be used in the treatment of gallstones under normal circumstances, on the premise...

  • Gilteritinib Fumarate

    Sandoo Pharmaceutica is a professional pharmaceutical intermediates manufacturer. We provide good quality Gilteritinib Fumarate Cas: 1254053-43-4. Welcome and we look forward to your inquiry!

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products can be produced in ordinary chemical plants without obtaining a pharmaceutical production license. As long as the technical indicators meet certain level requirements, they can be used to participate in the synthesis and production of drugs.

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    API is fundamental to the modern drug manufacturing process and cutting cost should not be the only criteria that can be applied to the production of an active pharmaceutical ingredient as it can adversely affect human health if the above-mentioned regulations and practices are not followed strictly.

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

Related Search

CAS NO 113507-06-5

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept